ACADIA Pharmaceuticals Inc. ( ACAD) - Stock Earnings
ACAD Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q3 | 71.8 million USD | 278.6 million USD |
| 2025Q4 | 273.6 million USD | 284.0 million USD |
| 2026Q1 | 3.6 million USD | 268.1 million USD |
| 2026Q2 Est. | — | — |
| 2026Q3 Est. | — | — |
| 2026Q4 Est. | — | — |
ACAD Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -61.3 million USD | 726.4 million USD |
| 2024 | 226.5 million USD | 957.8 million USD |
| 2025 | 391.0 million USD | 1.1 billion USD |
| 2026 Est. | — | — |
ACAD
Price: $21.26
52 week price:
Earnings Per Share: 2.21 USD
P/E Ratio: 9.86
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.4 million
Ebitda: -65.6 millionMarket Capitalization: 3.7 billion